Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells
Номер патента: EP1448584A2
Опубликовано: 25-08-2004
Автор(ы): Giuliana Salvatore, Ira H. Pastan, Richard Beers, Robert J. Kreitman
Принадлежит: US Department of Health and Human Services
Опубликовано: 25-08-2004
Автор(ы): Giuliana Salvatore, Ira H. Pastan, Richard Beers, Robert J. Kreitman
Принадлежит: US Department of Health and Human Services
Реферат: Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells.
Mutated Anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
Номер патента: US7777019B2. Автор: Ira Pastan,Richard Beers,Giuliana Salvatore,Robert J. Kreitman. Владелец: US Department of Health and Human Services. Дата публикации: 2010-08-17.